The only second-generation JAK inhibitor selective for relief of itch and inflammation
Relief never felt so simple
The Future of Itch Relief
Selective & Effective Relief
Numelvi® (atinvicitinib tablets) is a second-generation Janus kinase (JAK) inhibitor.
Numelvi® provides an effective first-line treatment in dogs 6 months of age and older and is indicated for
- pruritus associated with allergic dermatitis and atopic dermatitis
- clinical manifestations of atopic dermatitis
The only JAK inhibitor least 10X more selective for JAK1*¹, providing a favourable safety profile1 and owner peace of mind.
The only JAK inhibitor licensed in dogs as young as 6 months old.¹
Starts relieving itch within 2–4 hours**, providing dogs and owners relief quickly.
Once-daily dosing from day 1¹, keeping it simple, reducing up-front costs and eliminating rebound itch.
Why selectivity matters
Numelvi is the only second-generation JAK inhibitor selective for itch and inflammation.
JAK1 is the primary driver of itch and inflammation
High selectivity for JAK1 helps minimise interference with other JAK enzymes crucial for immune system function and haematopoiesis
First-generation JAK inhibitors target JAK enzymes with little to no selectivity¹
Numelvi is at least 10x more selective for JAK1* ¹, providing a favourable safety profile¹ and owner peace of mind
Dr Stephen Shaw on why JAK selectivity matters
How selectivity supports safety
Because Numelvi is more than 10x selective for JAK1*, it gives owners peace of mind by providing:
- A favourable safety profile¹
- The only JAK inhibitor licensed for dogs as young as 6 months1
- No known interactions with routine treatment¹
- No adverse clinical effects related to treatment when used concomitantly with vaccination, including rabies vaccination¹
- No requirements for periodic blood and urine monitoring¹
- Reduced inflammation-associated white blood cell counts (within reference range)1
How selectivity supports safety
Because Numelvi is at least 10x as selective for JAK1*, it gives owners peace of mind by providing:
- A favourable safety profile¹
- The only JAK inhibitor licensed for dogs as young as 6 months1
- No known interactions with routine treatments¹
- No adverse clinical effects related to treatment when used concomitantly with vaccination, including rabies vaccination¹
- No requirements for periodic blood and urine testing¹
- Reduced inflammation-associated white blood cell counts (within reference range)1
The future of itch relief
offers reassuring safety for patients.
Numelvi provides quick and effective relief
Itch relief starts within 2-4 hours**
Significant reduction in itch from the first dose4
Clinically relevant reduction in itch in >81% of dogs within 1 week4
Reduction of allergy-mediated inflammation
Available in 4 Convenient Strengths
Simple dosing: dogs weighing 3.0–39.5 kg require half or one tablet daily
Dogs outside the listed weight bands, for example dogs above 79 kg bodyweight, can be dosed with a combination of full and/or half tablets of the appropriate tablet strengths to achieve a target dose of 0.8–1.2 mg atinvicitinib/kg bodyweight. Available tablet strengths do not allow for accurate dosing of dogs weighing less than 2 kg bodyweight.
Compare Numelvi® to first-generation JAK inhibitors
*Over the other JAK enzymes in in vitro assays.
Have a question about Numelvi®?
Simplicity and Convenience
Simple for Veterinarians
- Proven safety profile for dogs and puppies as young as 6 months of age
- Available in pack sizes of 30 and 90 tablets
- Available in four pack strengths (4.8 mg, 7.2 mg, 21.6 mg & 31.6 mg)
- Does not require any special storage conditions
- Shelf life as packaged for sale is 36 months
Simple for Pet Owners
- Once-daily dosing from the start
- Consistent itch relief with consistent dosing
- Reassuring safety profile
Experts and Case Studies
Eleanor Hughes – RCVS-recognised Specialist in Veterinary Dermatology
“It is more specific, less side effects because it’s selective. Once daily dosing, it’s very quick onset and people don’t have to remember to change the dose”
Simon Want – RCVS-recognised Specialist in Veterinary Dermatology
“I am very excited, there is a new entry for a new JAK inhibitor for treating atopic dermatitis, giving us more options to treat more of our pets”
Simon Want – RCVS-recognised Specialist in Veterinary Dermatology
“I am very excited, there is a new entry for a new JAK inhibitor for treating atopic dermatitis, giving us more options to treat more of our pets”
Eleanor Hughes – RCVS-recognised Specialist in Veterinary Dermatology
“It is more specific, less side effects because it’s selective. Once daily dosing, it’s very quick onset and people don’t have to remember to change the dose”
Case Studies coming soon…
Want to learn more about Numelvi?
* Over the other JAK enzymes in in vitro assays.
** Based on a canine interleukin-31 induced pruritus model
References
- Numelvi® Summary of product characteristics
- Gonzalez AJ, Bowman JW, Fici GJ, et al. J Vet Pharmacol Ther. 2014;37(4):317-324
- MSD Internal Study Summary REF 11202. MSD Animal Health
- MSD Internal Study Summary REF 11194. MSD Animal Health
- Cosgrove SB, Wren JA, Cleaver DM, et al. Vet Dermatol. 2013;24(5):479-e114
- Kowalski T, Prohaczik A, Locke K, et al. The second-generation Janus kinase inhibitor atinvicitinib significantly reduces pruritus 2-4 hours after dosing dogs in a canine interleukin-31 model. European Veterinary Dermatology Congress, 11-13 Sep 2025, Bilbao, Spain. [Abstract]
Want to make itch relief simple in your practice? Fill in the form below today.
Please fill out the form below to request a call from an MSD Animal Health representative.
“*” indicates required fields
